Axa

The accelerated approval of the first new Alzheimer's treatment in almost two decades looks set to drive a new wave of biotech innovation and investment.

Last year saw a surge in cyberattacks

Fund 'no longer provides value'

Lockdown leaders proving a hit

Whetting investors' appetites with viable, long-term options

Managed by Nick Hayes

Investor sentiment 'turns sour'

'Good for the people and good for the planet'

Boutiques well represented

Marco Morelli joins from Monte dei Paschi di Siena